Literature DB >> 24061076

What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?

Shervin Assassi1, Maureen D Mayes.   

Abstract

PURPOSE OF REVIEW: The purpose of this study is to review recent hypothesis-driven studies that utilize global gene expression data for elucidating the molecular basis of systemic sclerosis (SSc) and its various clinical manifestations. RECENT
FINDINGS: The longitudinal skin gene expression studies indicate that the previously identified molecular subsets are stable over time and might identify inherent subgroups of SSc patients. Skin transcript follow-up studies indicate that the Wnt/β-catenin pathway plays an important role in promotion of fibrogenesis in fibroblasts and preadipocytes. Furthermore, the transcript profile of sclerodermatous graft-versus-host disease (sclGVHD) mice resembles the skin transcriptomes of a subgroup of SSc patientswith IL13/IL4-inducible skin signature wherein the profibrotic chemokine CCL2 plays a key role. The comparison of skin biopsies from SSc patients to skin lesions of patients with cutaneous lupus and dermatomyositis has provided valuable information about the interferon (IFN) signature in these autoimmune diseases. Furthermore, plasma IFN-inducible chemokines correlate with the IFN gene expression score in SSc patients, enabling researchers to examine this molecular signature in large SSc cohorts with serum or plasma collection.
SUMMARY: Global gene expression profiling in skin and peripheral blood can contribute to a better understanding of SSc pathogenesis and identify novel biomarkers and therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061076      PMCID: PMC3929183          DOI: 10.1097/01.bor.0000434672.77891.41

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  35 in total

1.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients.

Authors:  F K Tan; X Zhou; M D Mayes; P Gourh; X Guo; C Marcum; L Jin; F C Arnett
Journal:  Rheumatology (Oxford)       Date:  2006-01-17       Impact factor: 7.580

2.  Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts.

Authors:  Humphrey Gardner; Jeffrey R Shearstone; Raj Bandaru; Tom Crowell; Matthew Lynes; Maria Trojanowska; Jaspreet Pannu; Edwin Smith; Stefania Jablonska; Maria Blaszczyk; Filemon K Tan; Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2006-06

3.  Identification of genes selectively regulated by IFNs in endothelial cells.

Authors:  Stefano Indraccolo; Ulrich Pfeffer; Sonia Minuzzo; Giovanni Esposito; Valeria Roni; Susanna Mandruzzato; Nicoletta Ferrari; Luca Anfosso; Raffaella Dell'Eva; Douglas M Noonan; Luigi Chieco-Bianchi; Adriana Albini; Alberto Amadori
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

4.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Authors:  Minoru Hasegawa; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2010-11-04       Impact factor: 2.980

5.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

6.  Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension.

Authors:  Eileen Hsu; Haiwen Shi; Rick M Jordan; James Lyons-Weiler; Joseph M Pilewski; Carol A Feghali-Bostwick
Journal:  Arthritis Rheum       Date:  2011-03

7.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

8.  Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.

Authors:  Asish K Ghosh; Swati Bhattacharyya; Gabriella Lakos; Shu-Jen Chen; Yasuji Mori; John Varga
Journal:  Arthritis Rheum       Date:  2004-04

9.  PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis.

Authors:  Jun Wei; Asish K Ghosh; Jennifer L Sargent; Kazuhiro Komura; Minghua Wu; Qi-Quan Huang; Manu Jain; Michael L Whitfield; Carol Feghali-Bostwick; John Varga
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

10.  Systemic and cell type-specific gene expression patterns in scleroderma skin.

Authors:  Michael L Whitfield; Deborah R Finlay; John Isaac Murray; Olga G Troyanskaya; Jen-Tsan Chi; Alexander Pergamenschikov; Timothy H McCalmont; Patrick O Brown; David Botstein; M Kari Connolly
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

View more
  8 in total

1.  Minor salivary gland fibrosis in Sjögren's syndrome is elevated, associated with focus score and not solely a consequence of aging.

Authors:  Kerry M Leehan; Nathan P Pezant; Astrid Rasmussen; Kiely Grundahl; Jacen S Moore; Lida Radfar; David M Lewis; Donald U Stone; Christopher J Lessard; Nelson L Rhodus; Barbara M Segal; R Hal Scofield; Kathy L Sivils; Courtney Montgomery; A Darise Farris
Journal:  Clin Exp Rheumatol       Date:  2017-10-23       Impact factor: 4.473

2.  Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.

Authors:  Sonsoles Piera-Velazquez; Alma Makul; Sergio A Jiménez
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

Review 3.  Genetics, Epigenetics, and Genomics of Systemic Sclerosis.

Authors:  Gloria Salazar; Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2015-05-20       Impact factor: 2.670

4.  Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.

Authors:  Brian Skaug; Dinesh Khanna; William R Swindell; Monique E Hinchcliff; Tracy M Frech; Virginia D Steen; Faye N Hant; Jessica K Gordon; Ami A Shah; Lisha Zhu; W Jim Zheng; Jeffrey L Browning; Alexander M S Barron; Minghua Wu; Sudha Visvanathan; Patrick Baum; Jennifer M Franks; Michael L Whitfield; Victoria K Shanmugam; Robyn T Domsic; Flavia V Castelino; Elana J Bernstein; Nancy Wareing; Marka A Lyons; Jun Ying; Julio Charles; Maureen D Mayes; Shervin Assassi
Journal:  Ann Rheum Dis       Date:  2019-11-25       Impact factor: 19.103

5.  In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.

Authors:  Yukihiro Kitanaga; Emiko Imamura; Yutaka Nakahara; Hidehiko Fukahori; Yasutomo Fujii; Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

6.  Wnt/β-catenin signaling mediates the abnormal osteogenic and adipogenic capabilities of bone marrow mesenchymal stem cells from chronic graft-versus-host disease patients.

Authors:  Han-Zhou Qi; Yi-Ling Ye; Yuan Suo; Hong Qu; Hai-Yan Zhang; Kai-Bo Yang; Zhi-Ping Fan; Fen Huang; Li Xuan; Yan-Qiu Chen; Hua Jin; Qi-Fa Liu
Journal:  Cell Death Dis       Date:  2021-03-23       Impact factor: 8.469

7.  Autophagy-related genes are potential diagnostic biomarkers for dermatomyositis.

Authors:  Le Wang; Dalang Fang; Yuan Liu
Journal:  Ann Transl Med       Date:  2022-02

Review 8.  Emerging Role and Therapeutic Implication of Wnt Signaling Pathways in Autoimmune Diseases.

Authors:  Juan Shi; Shuhong Chi; Jing Xue; Jiali Yang; Feng Li; Xiaoming Liu
Journal:  J Immunol Res       Date:  2016-03-27       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.